Brendan Smith, an analyst from TD Cowen, maintained the Buy rating on Repligen. The associated price target is $200.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brendan Smith has given his Buy rating due to a combination of factors that highlight both prudent guidance and meaningful upside potential. He views the new 2026 revenue outlook as intentionally cautious, particularly at the low end, noting that early‐year trends and a modest sequential dip in Q1 revenue should help reduce execution risk and support the company’s ability to meet or exceed its targets.
He also emphasizes that Repligen’s diversified bioprocessing portfolio is delivering above‑market growth, which he believes justifies a premium valuation versus peers and supports his $200 price target. While near‑term macro issues such as tariffs and MFN‑related ordering pauses are acknowledged in the outlook, Smith argues these headwinds are already embedded in guidance, leaving multiple avenues for derisked upside as core businesses continue to perform well and potential policy shifts ease the impact over time.